Basel, Switzerland – This week Novartis released topline results from the Phase III APPEAR-C3G study showing that its oral factor B inhibitor iptacopan significantly reduced protein in the urine of patients with C3 glomerulopathy, an ultra-rare and progressive kidney disease. In APPEAR-C3G, twice-daily treatment with 200-mg iptacopan—when given on top...
treatment News
Basel, Switzerland – A new way to treat a painful skin condition shows promise in a phase 2 trial, according to a late-breaking presentation at the American Academy of Dermatology (AAD) Association annual meeting. Novartis’ remibrutinib was well tolerated and showed high responder rates compared with placebo in patients with...
CHICAGO – A newly developed artificial intelligence (AI) system that analyzes specialized MRIs of the brain accurately diagnosed children between the ages of 24 and 48 months with autism at a 98.5% accuracy rate, according to research being presented next week at the annual meeting of the Radiological Society of...
Sendai, Japan – Researchers at Tohoku University have discovered a new approach for treating lymph node metastasis. Anticancer drugs are administered directly into the LNs under ultrasound guidance (Lymphatic Drug Delivery System or LDDS) to target sentinel lymph nodes (LNs) and generate antitumor effects locally, preventing distant metastasis. This approach...
CHICAGO – A newly developed artificial intelligence (AI) system that analyzes specialized MRIs of the brain accurately diagnosed children between the ages of 24 and 48 months with autism at a 98.5% accuracy rate, according to research being presented next week at the annual meeting of the Radiological Society of...
Atlanta, Georgia – A Georgia State University startup company focused on developing cancer-fighting tools and treatments is making new strides by advancing its technology to the next phase of clinical trials. Georgia State’s Office of Technology Transfer reports that Da Zen Theranostics is preparing an innovation known as DZ-002 for its next significant milestone,...
SAN DIEGO, CA ― Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a major indicator of clinical improvement – compared with standard-of-care ruxolitinib monotherapy for adult patients with intermediate or high-risk myelofibrosis, a rare bone marrow cancer, according to...
Dresden, Germany – Tuberculosis (TB) is a prevalent infectious disease that affects millions of people each year. It was previously the leading cause of death from a single pathogen before the COVID-19 pandemic. Detecting TB early is challenging because the bacterium Mycobacterium tuberculosis (Mtb) can hide in human macrophages, which...
SAN DIEGO ― Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated early positive results from novel therapies targeting menin for the treatment of relapsed or refractory acute leukemias with specific genetic alterations. Results from the studies were shared today in oral presentations at the...
Reston, VA — A new molecular imaging technique that pairs a novel tracer with a next-generation PET/CT scanner can identify neuroblastoma in children with high sensitivity, requiring a scan time of only minutes and no sedation or anesthesia. With its ability to accurately diagnose neuroblastoma, this technique, known as 18F-MFBG LAFOV...